NGDC - GSA for Human

HRA003043

HRA003043.xlsx

Title:

Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: A prospective single-arm trial

Release date:

2022-09-15

Description:

20 locally advanced oral squamous cell carcinoma patients were enrolled. Neoadjuvant immunochemotherapy (NAICT) was well-tolerated with low incidence of grade 3-4 adverse events (AEs) in three patients (15%). Using pathological evaluation for NAICT, the major pathologic response (MPR) rate was 60% (12/20), including 30% (6/20) pCR. MPR was archived in all 4 patients with combined positive score of PD-L1>10. Using radiographical evaluation, there were 10% of CR and 50% of PR. The pathological and radiographical response was consistent in linear regression analysis (P<0.001). The pathological response pattern to NAICT was scatter pattern in 92.9% (13/14) of patients, with multiple residual foci. Patients with higher TMB and more immune activation cells in biopsies tended to show higher MPR rate, respectively. More tertiary lymphoid structure was found in the post-NAICT surgical specimens than pre-NAICT biopsies (P=0.03), especially in the MPR group (P=0.009).

Data Accessibility:

Controlled access Request Data

BioProject:

PRJCA011820

Study type:

Disease Study

Disease name:

head and neck cancer

Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.

DAC NO.:

HDAC001750

DAC name:

Neoadjuvant

Contact person:

Zhong Laiping

Email:

zhonglp@hotmail.com

Description:

DAC for Neoadjuvant

Aspera Command Line